Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2026 06:00 ET | Source: Teladoc Health, Inc.

Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care

Teladoc One is a model of care delivered as a single, predictive and adaptive experience to drive better health outcomes and address the rising total cost of care Multidisciplinary care teams, paired...
July 16, 2026 01:00 ET | Source: Boehringer Ingelheim

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Not intended for UK and US audiencesBoehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people...
June 19, 2026 01:15 ET | Source: Novo Nordisk Foundation

New European initiative to accelerate drug discovery for cardiometabolic diseases

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).
June 02, 2026 07:00 ET | Source: Augustine Therapeutics

Augustine Therapeutics to Present Late-Breaking Poster at the American Diabetes Association’s 86th Scientific Sessions

Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidates LEUVEN, Belgium – 2 June 2026 – Augustine Therapeutics NV (“Augustine” or “the Company”), a...
January 07, 2026 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) In...
November 17, 2025 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases

Imbria extends Series B financing with new investor AXA IM Alts to advance ninerafaxstat and address urgent global cardiovascular health challenges.
September 16, 2025 02:30 ET | Source: Cantoni Therapeutics

Cantoni Therapeutics secures financing to advance novel non-incretin obesity drug into IND enabling phase

Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF)Cantoni...
August 19, 2025 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer

BOSTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company revolutionizing cardiovascular disease treatment by targeting cardiac energy metabolism,...
June 23, 2025 16:15 ET | Source: iBio, Inc.

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE...
June 23, 2025 08:00 ET | Source: Corxel Pharmaceuticals

Data from the Phase 2 Clinical Trial of CX11/VCT220 in China Presented at ADA 2025

Patients treated with CX11 (also designated as VCT220) achieved a 9.7% and 9.4% decrease in body weight from baseline after 16 weeks (p≤0.001) in the 160 mg fast and slow titration cohorts,...